Rivoglitazone HCl + rivoglitazone HCl + rivoglitazone HCl + placebo + pioglitazone HCl + pioglitazone HCl + pioglitazone HCl 45 mg + placebo + metformin
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Nov 14, 2007 → May 23, 2008
NCT ID
NCT00571519About Rivoglitazone HCl + rivoglitazone HCl + rivoglitazone HCl + placebo + pioglitazone HCl + pioglitazone HCl + pioglitazone HCl 45 mg + placebo + metformin
Rivoglitazone HCl + rivoglitazone HCl + rivoglitazone HCl + placebo + pioglitazone HCl + pioglitazone HCl + pioglitazone HCl 45 mg + placebo + metformin is a phase 3 stage product being developed by Daiichi Sankyo for Type 2 Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00571519. Target conditions include Type 2 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00571519 | Phase 3 | Terminated |
Competing Products
20 competing products in Type 2 Diabetes Mellitus